GUTS -
Fractyl Health, Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
1.35 0.01 (0.74%) |
--- |
--- |
-0.01 (-0.71%) |
0.04 (2.96%) |
-0.05 (-3.62%) |
0.03 (2.26%) |
0.03 (2.26%) |
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Earnings & Ratios
- Basic EPS:
- -0.57
- Diluted EPS:
- -0.57
- Basic P/E:
- -2.386
- Diluted P/E:
- -2.386
- RSI(14) 1m:
- 1.98
- VWAP:
- 1.36
- RVol:
Events
Period |
Kind |
Movement |
Occurred At |
Related News
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
Sep 26, 2025 11:00
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Sep 03, 2025 11:00
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
Jun 13, 2025 11:00
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
May 19, 2025 11:00
Fractyl Health to Participate in the Upcoming December Conferences
Nov 26, 2024 12:00
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
Oct 29, 2024 11:00
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Jun 25, 2024 11:00
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Jun 24, 2024 10:00
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
Jun 23, 2024 17:30
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024 10:00